Cryoablation, Percutaneous Alcohol Injection, and Radiofrequency Ablation for Treatment of Neuroendocrine Liver Metastases

2001 ◽  
Vol 25 (6) ◽  
pp. 693-696 ◽  
Author(s):  
Allan E. Siperstein ◽  
Eren Berber
2005 ◽  
Vol 30 (4) ◽  
pp. 427-434 ◽  
Author(s):  
A. Elvin ◽  
B. Skogseid ◽  
P. Hellman

2005 ◽  
Vol 30 (4) ◽  
pp. 435-441 ◽  
Author(s):  
A. Gillams ◽  
A. Cassoni ◽  
G. Conway ◽  
W. Lees

2015 ◽  
Vol 26 (7) ◽  
pp. 935-942.e1 ◽  
Author(s):  
Helen Mohan ◽  
Patrick Nicholson ◽  
Des C. Winter ◽  
Donal O’Shea ◽  
Dermot O’Toole ◽  
...  

Author(s):  
J Genov ◽  
N Grigorov ◽  
R Mitova ◽  
B Golemanov ◽  
L Dinkov ◽  
...  

2019 ◽  
Vol 98 (10) ◽  

Introduction: Radical liver resection is the only method for the treatment of patients with colorectal liver metastases (CLM); however, only 20–30% of patients with CLMs can be radically treated. Radiofrequency ablation (RFA) is one of the possible methods of palliative treatment in such patients. Methods: RFA was performed in 381 patients with CLMs between 01 Jan 2001 and 31 Dec 2018. The mean age of the patients was 65.2±8.7 years. The male to female ratio was 2:1. Open laparotomy was done in 238 (62.5%) patients and the CT-navigated transcutaneous approach was used in 143 (37.5%) patients. CLMs <5 cm (usually <3 cm) in diameter were the indication for RFA. We used RFA as the only method in 334 (87.6%) patients; RFA in combination with resection was used in 36 (9.4%), and with multi-stage resection in 11 (3%) patients. We performed RFA in a solitary CLM in 170 (44.6%) patients, and in 2−5 CLMs in 211 (55.6%) patients. We performed computed tomography in each patient 48 hours after procedure. Results: The 30-day postoperative mortality was zero. Complications were present in 4.8% of transcutaneous and in 14.2% of open procedures, respectively, in the 30-day postoperative period. One-, 3-, 5- and 10-year overall survival rates were 94.8, 66.8, 43.9 and 16.6%, respectively, in patients undergoing RFA, and 90.6, 69.1, 52.8 and 39.2%, respectively, in patients with liver resections. Disease free survival was 63.2, 30.1, 18.4 and 13.1%, respectively, in the same patients after RFA, and 71.1, 33.3, 22.8 and 15.5%, respectively, after liver resections. Conclusion: RFA is a palliative thermal ablation method, which is one of therapeutic options in patients with radically non-resectable CLMs. RFA is useful especially in a non-resectable, or resectable (but for the price of large liver resection) solitary CLM <3 cm in diameter and in CLM relapses. RFA is also part of multi-stage liver procedures.


Sign in / Sign up

Export Citation Format

Share Document